Sun Pharm Drug Patent Portfolio
Sun Pharm owns 12 orange book drugs protected by 37 US patents with Ezallor Sprinkle having the least patent protection, holding only 1 patent. And Winlevi with maximum patent protection, holding 9 patents. Given below is the list of Sun Pharm's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11052196 | Method of injecting octreotide acetate into the body | 03 Nov, 2040 | Active |
| US11246991 | Electrolysis-resistant coupling assembly for valves | 03 Nov, 2040 | Active |
| US11534553 | Method of injecting octreotide acetate into the body | 03 Nov, 2040 | Active |
| US10342850 | Octreotide injection | 15 May, 2038 | Active |
| US10413525 | Duloxetine sprinkles | 13 Apr, 2037 | Active |
| US10959982 | Duloxetine sprinkles | 13 Apr, 2037 | Active |
| US11202772 | Duloxetine sprinkles | 13 Apr, 2037 | Active |
| US12171742 | Duloxetine sprinkles | 13 Apr, 2037 | Active |
| US9839626 | Duloxetine sprinkles | 13 Apr, 2037 | Active |
| US10918694 | Topical cyclosporine-containing formulations and uses thereof | 28 Feb, 2037 | Active |
| US11951153 | Topical cyclosporine-containing formulations and uses thereof | 28 Feb, 2037 | Active |
| US10266523 | Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof | 30 Mar, 2036 | Active |
| US10413543 | Stable multiparticulate pharmaceutical composition of rosuvastatin | 12 Feb, 2036 | Active |
| US9700535 | Oral pharmaceutical composition of isotretinoin | 04 Aug, 2035 | Active |
| US9750711 | Low dose oral pharmaceutical composition of isotretinoin | 29 May, 2035 | Active |
| US9962336 | Extended release suspension compositions | 01 May, 2035 | Active |
| US10292990 | Abiraterone steroid formulation | 20 May, 2034 | Active |
| US9889144 | Abiraterone acetate formulation and methods of use | 17 Mar, 2034 | Active |
| US10441630 | Topical formulations and uses thereof | 23 Aug, 2033 | Active |
| US8980839 | Topical aqueous nanomicellar, ophthalmic solutions and uses thereof | 23 Aug, 2033 | Active |
| US9937225 | Topical formulations and uses thereof | 23 Aug, 2033 | Active |
| US9241948 | Ready to be infused gemcetabine solution | 01 Jul, 2033 | Active |
| US8785427 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | 25 Jul, 2030 | Active |
| US8063043 | Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide | 15 Sep, 2029 | Active |
| US9629852 | Ophthalmic composition comprising a prostaglandin | 12 Sep, 2029 | Active |
| US8778999 | Non-steroidal anti-inflammatory ophthalmic compositions | 07 Aug, 2029 | Active |
| US8178563 | Compounds and compositions as hedgehog pathway modulators | 24 Jul, 2029 | Active |
| USRE50218 | Non-steroidal anti-inflammatory ophthalmic compositions | 05 Mar, 2029 | Active |
| US9433628 | Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives | 28 Feb, 2029 | Active |
| US11207332 | Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives | 20 Nov, 2028 | Active |
| US9539262 | Ophthalmic composition comprising a prostaglandin | 15 Oct, 2028 | Active |
| US10159682 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | 14 Aug, 2028 | Active |
| US11938141 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | 24 Jul, 2028 | Active |
| US9486458 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | 24 Jul, 2028 | Active |
| US8143240 | 17α, 21-dihydroxypregnene esters as antiandrogenic agents | 12 Jan, 2026 | Active |
| US8865690 | 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents | 24 Jul, 2025 | Active |
| US9211295 | 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents | 31 May, 2025 | Active |
Latest Legal Activities on Sun Pharm's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Sun Pharm.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Jul, 2024 | US9539262 |
|
Electronic Review
Critical
| 07 Jun, 2024 | US11951153 |
|
Interim Patent Term Extension Granted
Critical
| 22 May, 2024 | US8865690 |
|
Interim Patent Term Extension Granted
Critical
| 22 May, 2024 | US9211295 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 May, 2024 | US9486458 |
| Mail Patent eGrant Notification | 09 Apr, 2024 | US11951153 |
|
Recordation of Patent Grant Mailed
Critical
| 09 Apr, 2024 | US11951153 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 09 Apr, 2024 | US11951153 |
|
Email Notification
Critical
| 09 Apr, 2024 | US11951153 |
| Patent eGrant Notification | 09 Apr, 2024 | US11951153 |
| Recordation of Patent eGrant | 09 Apr, 2024 | US11951153 |
|
Email Notification
Critical
| 21 Mar, 2024 | US11951153 |
|
Issue Notification Mailed
Critical
| 20 Mar, 2024 | US11951153 |
| Dispatch to FDC | 07 Mar, 2024 | US11951153 |
|
Email Notification
Critical
| 07 Mar, 2024 | US11951153 |
Sun Pharm's Drug Patent Litigations
Sun Pharm's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 06, 2013, against patent number US9629852. The petitioner , challenged the validity of this patent, with Ajay Jaysingh Khopade et al as the respondent. Click below to track the latest information on how companies are challenging Sun Pharm's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9629852 | June, 2013 |
Decision
(26 Apr, 2016)
| Ajay Jaysingh Khopade et al | |
Sun Pharm Drug Patents' Oppositions Filed in EPO
Sun Pharm drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 08, 2016, by Generics (U.K.) Limited. This opposition was filed on patent number EP13165862A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP15786792A | Aug, 2021 | Reckitt Benckiser Health Limited | Granted and Under Opposition |
| EP13165862A | Jan, 2016 | Generics (U.K.) Limited | Patent maintained as amended |
Sun Pharm's Family Patents
Sun Pharm Drug List
Given below is the complete list of Sun Pharm's drugs and the patents protecting them.
1. Absorica Ld
Absorica Ld is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9700535 | Oral pharmaceutical composition of isotretinoin |
04 Aug, 2035
(10 years from now)
| Active |
| US9750711 | Low dose oral pharmaceutical composition of isotretinoin |
29 May, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Absorica Ld's drug page
2. Bromsite
Bromsite is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8778999 | Non-steroidal anti-inflammatory ophthalmic compositions |
07 Aug, 2029
(4 years from now)
| Active |
| USRE50218 | Non-steroidal anti-inflammatory ophthalmic compositions |
05 Mar, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bromsite's drug page
3. Bynfezia Pen
Bynfezia Pen is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11052196 | Method of injecting octreotide acetate into the body |
03 Nov, 2040
(15 years from now)
| Active |
| US11246991 | Electrolysis-resistant coupling assembly for valves |
03 Nov, 2040
(15 years from now)
| Active |
| US11534553 | Method of injecting octreotide acetate into the body |
03 Nov, 2040
(15 years from now)
| Active |
| US10342850 | Octreotide injection |
15 May, 2038
(13 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bynfezia Pen's drug page
4. Cequa
Cequa is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10918694 | Topical cyclosporine-containing formulations and uses thereof |
28 Feb, 2037
(11 years from now)
| Active |
| US11951153 | Topical cyclosporine-containing formulations and uses thereof |
28 Feb, 2037
(11 years from now)
| Active |
| US10441630 | Topical formulations and uses thereof |
23 Aug, 2033
(8 years from now)
| Active |
| US8980839 | Topical aqueous nanomicellar, ophthalmic solutions and uses thereof |
23 Aug, 2033
(8 years from now)
| Active |
| US9937225 | Topical formulations and uses thereof |
23 Aug, 2033
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cequa's drug page
5. Drizalma Sprinkle
Drizalma Sprinkle is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10413525 | Duloxetine sprinkles |
13 Apr, 2037
(11 years from now)
| Active |
| US10959982 | Duloxetine sprinkles |
13 Apr, 2037
(11 years from now)
| Active |
| US11202772 | Duloxetine sprinkles |
13 Apr, 2037
(11 years from now)
| Active |
| US12171742 | Duloxetine sprinkles |
13 Apr, 2037
(11 years from now)
| Active |
| US9839626 | Duloxetine sprinkles |
13 Apr, 2037
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Drizalma Sprinkle's drug page
Explore Our Curated Drug Screens
6. Ezallor Sprinkle
Ezallor Sprinkle is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10413543 | Stable multiparticulate pharmaceutical composition of rosuvastatin |
12 Feb, 2036
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ezallor Sprinkle's drug page
7. Infugem
Infugem is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9241948 | Ready to be infused gemcetabine solution |
01 Jul, 2033
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Infugem's drug page
8. Odomzo
Odomzo is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10266523 | Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof |
30 Mar, 2036
(10 years from now)
| Active |
| US8063043 | Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide |
15 Sep, 2029
(4 years from now)
| Active |
| US8178563 | Compounds and compositions as hedgehog pathway modulators |
24 Jul, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Odomzo's drug page
9. Riomet Er
Riomet Er is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9962336 | Extended release suspension compositions |
01 May, 2035
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Riomet Er's drug page
10. Winlevi
Winlevi is protected by 9 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8785427 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
25 Jul, 2030
(5 years from now)
| Active |
| US9433628 | Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
28 Feb, 2029
(3 years from now)
| Active |
| US11207332 | Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
20 Nov, 2028
(3 years from now)
| Active |
| US10159682 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
14 Aug, 2028
(3 years from now)
| Active |
| US11938141 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
24 Jul, 2028
(3 years from now)
| Active |
| US9486458 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
24 Jul, 2028
(3 years from now)
| Active |
| US8143240 | 17α, 21-dihydroxypregnene esters as antiandrogenic agents |
12 Jan, 2026
(8 months from now)
| Active |
| US8865690 | 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents |
24 Jul, 2025
(2 months from now)
| Active |
| US9211295 | 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents |
31 May, 2025
(21 days from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Winlevi's drug page
11. Xelpros
Xelpros is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9629852 | Ophthalmic composition comprising a prostaglandin |
12 Sep, 2029
(4 years from now)
| Active |
| US9539262 | Ophthalmic composition comprising a prostaglandin |
15 Oct, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xelpros's drug page
12. Yonsa
Yonsa is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10292990 | Abiraterone steroid formulation |
20 May, 2034
(9 years from now)
| Active |
| US9889144 | Abiraterone acetate formulation and methods of use |
17 Mar, 2034
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Yonsa's drug page